Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;13:841766. doi: 10.3389/fphar.2022.841766

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Ruiz de Martín Esteban, Benito-Cuesta, Terradillos, Martínez-Relimpio, Arnanz, Ruiz-Pérez, Korn, Raposo, Sarott, Westphal, Elezgarai, Carreira, Hillard, Grether, Grandes, Grande and Romero.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Signaling cascades regulated by the activation and deletion of cannabinoid CB₂ receptors. (A) cAMP and p-CREB (B) levels were significantly decreased by the treatment with the CB₂ agonist, remaining unaltered in samples from CB₂-null mice. (C) p-p38MAPK levels were significantly elevated by the exposure to the agonist; in addition, samples from 5xFAD/CB₂ ^-/- mice exhibited significantly lower levels. (D) p-ERK levels were not modified by the treatment with the CB₂ agonist or the genetic deletion of the receptor. Two-way ANOVA followed by Tukey’s post-hoc test. *<p0.05; **<p0.01; ***<p0.001; ****<p0.0001. N = 4–9 mice per group. Data represent mean ± SEM.